Pages

Tuesday, March 17, 2020

Investigational Drugs and Biologics for Corona virus (COVID-19)


As of now, no drugs or biologics have been proven to be effective for the prevention or treatment of COVID-19. There are many investigational drugs and biologics under investigation for COVID-19. Hopefully some of them will be available for use in the near future. Some may be used in severe cases even before they are approved by the FDA.

Antiviral Agents:
  • Remdesivir
  • Lopinavir/ritonavir
  • Rintatolimod
  • Toll-like receptor 3 (TLR-3) agonist rintatolimod (Poly I:Poly C12U)
  • Ampligen; AIM ImmunoTech)
  • Azvudine (nucleoside reverse transcriptase inhibitor)
  • Danoprevir (NS3/4A HCV protease inhibitor)
  • Favipiravir (viral RNA polymerase inhibitor)

Immunomodulators and Other Investigational Therapies:
  • Ifenprodil (NP-120; Algernon Pharmaceuticals) Brilacidin
  • Remestemcel-L (Mesoblast Ltd) Eli Lilly and AbCellera are co-developing an antibody treatment .
  • Anti-SARS-CoV-2 polyclonal hyperimmune globulin (TAK-888; Takeda) is being developed to treat COVID-19 in high-risk patients.
  • Interleukin-6 inhibitors
  • Anti-malaria drugs: Hydroxychloroquine and chloroquine

Vaccines
  • INO-4800 (Inovio Pharmaceuticals):
  • mRNA-1273 (Moderna Inc
  • CureVac has an mRNA vaccine in development that is not yet ready for human testing.
  • COVID-19 S-Trimer (GlaxoSmithKline and Clover Biopharmaceuticals)
  • SARS-CoV-2 vaccine (Johnson & Johnson
  • Sanofi is also collaborating with BARDA to develop a vaccine using their recombinant DNA platform.
  • Several other vaccines are developed: by Novavax, Codagenix, Applied DNA Sciences and Takis Biotech, and  Altimmune, Inc.

To obtain more suggestions for laryngectomees how to cope with COVID-19 pandemic click the Laryngectomee Newsletter link.


 Corona virus (COVID-19)